News | January 07, 2020

Dapagliflozin Granted FDA Priority Review for Heart Failure With Reduced Ejection Fraction

The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) from AstraZeneca and granted priority review for dapagliflozin (Farxiga) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF) with and without type 2 diabetes (T2D).

January 7, 2020 — The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) from AstraZeneca and granted priority review for dapagliflozin (Farxiga) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF) with and without type 2 diabetes (T2D).

The Prescription Drug User Fee Act date, the FDA action date for this supplemental application, is scheduled for the second quarter of 2020.

The sNDA was based on results from the landmark Phase III DAPA-HF trial published in September 2019 in The New England Journal of Medicine, which showed dapagliflozin on top of standard of care reduced the incidence of the composite outcome of CV death or the worsening of HF versus placebo. Dapagliflozin is not indicated to reduce the risk of hospitalization for heart failure (hHF) in patients without diabetes, or to reduce the risk of CV death.

If cleared by the FDA, dapagliflozin will be the first medicine of its kind indicated to treat this population of patients with heart failure.

In September 2019, the FDA granted Fast Track designation for the development of FARXIGA in HF. In August 2019, the FDA also granted Fast Track designation for the development of dapagliflozin to delay the progression of renal failure and prevent CV and renal death in patients with chronic kidney disease, with and without T2D.

Dapagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D. In October 2019, the FDA also approved Farxiga to reduce the risk of hospitalization for heart failure in patients with T2D and established cardiovascular disease or multiple CV risk factors.

 

Related Content

Videos | Heart Failure

The University of Maryland Medical Center (UMMC) announced the first successful transplant of a genetically modified pig ...

Home January 11, 2022
Home
Feature | Heart Failure | By Dave Fornell, DAIC Editor

January 10, 2022 — The University of Maryland School of Medicine (UMSOM) and the University of Maryland Medical Center ...

Home January 10, 2022
Home
News | Heart Failure

December 16, 2021 — MVP Health Care and The University of Vermont Health Network recently announced their joint Medicare ...

Home December 16, 2021
Home
News | Heart Failure

November 19, 2021 — Adults treated with empagliflozin during hospitalization for acute heart failure experienced a ...

Home November 19, 2021
Home
News | Heart Failure

November 17, 2021 — Canagliflozin, a medication used to treat type 2 diabetes, was found to greatly improve symptoms and ...

Home November 17, 2021
Home
News | Heart Failure

November 10, 2021 — Ancora Heart Inc., a company developing a novel therapy to address heart failure, announced results ...

Home November 10, 2021
Home
News | Heart Failure

November 2, 2021 — Cardionomic Inc. announce initial U.S. enrollment in its global Cardiac Pulmonary Nerve Stimulation ...

Home November 02, 2021
Home
News | Heart Failure

October 27, 2021 — Impulse Dynamics announced the U.S. Food and Drug Administration approved a modification of labeling ...

Home October 27, 2021
Home
News | Heart Failure

October 1, 2021 — A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in ...

Home October 04, 2021
Home
News | Heart Failure

September 28, 2021 — Hemodynamic guided management using the CardioMEMS device may reduce heart failure hospitalizations ...

Home September 28, 2021
Home
Subscribe Now